Bottom line
PRHSX vs RYHIX: the short answer
PRHSX (T. Rowe Price Health Sciences Fund, Inc.) and RYHIX (Health Care Fund) share a meaningful slice of their top holdings — about 70% by weight.
But PRHSX is far broader, holding 279 positions to 135 for RYHIX, so beyond the top names it adds exposure RYHIX doesn't have.
PRHSX is cheaper at 0.83% vs 1.38% — a difference of $55 a year per $10,000 invested.
Over five years, RYHIX returned +5.1% a year vs +4.2% for PRHSX.
Updated Nov 19, 2026
PRHSX vs RYHIX side by side
| PRHSX | RYHIX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | T. Rowe Price | Guggenheim |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.83% | 1.38% |
| Annual cost per $10k | $83 | $138 |
| 10-yr cost on $10k (prospectus) | $1,025 | $1,709 |
| Max front load | — | — |
| 12b-1 fee | — | 0% |
| 1-yr return | +17.7% | +14.4% |
| 5-yr return (annualized) | +4.2% | +5.1% |
| 10-yr return (annualized) | +9.1% | +7.9% |
| Best quarter | +23.5% | +18.7% |
| Worst quarter | −15.8% | −14.4% |
| Net assets (fund) | $11.9B | $19.4M |
| Number of holdings | 279 | 135 |
| Portfolio turnover | 62% | 244% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PRHSX | RYHIX | Difference |
|---|---|---|---|
| 2025 | +17.7% | +14.4% | +3.3% |
| 2024 | +1.8% | +0.6% | +1.2% |
| 2023 | +3.1% | +5.8% | −2.8% |
| 2022 | −12.2% | −11.6% | −0.6% |
| 2021 | +13.3% | +19.2% | −6.0% |
| 2020 | +30.1% | +18.9% | +11.2% |
| 2019 | +29.1% | +22.8% | +6.3% |
| 2018 | +1.2% | +1.6% | −0.3% |
| 2017 | +28.0% | +23.5% | +4.5% |
| 2016 | −10.4% | −9.4% | −1.0% |
Source: Fund prospectus bar charts
Holdings overlap
17 of PRHSX's top 25 holdings also appear in RYHIX's top 25.
| Holding | PRHSX | RYHIX |
|---|---|---|
| Eli Lilly & Co | 14.28% | 3.63% |
| Johnson & Johnson | 6.63% | 2.88% |
| Unitedhealth Group Inc | 5.99% | 2.22% |
| Abbvie Inc | 5.10% | 2.52% |
| Merck & Co. Inc. | 4.01% | 2.04% |
| Gilead Sciences Inc | 2.82% | 1.39% |
| Thermo Fisher Scientific Inc | 2.52% | 1.61% |
| Vertex Pharmaceuticals Inc | 2.28% | 1.34% |
| Bristol-myers Squibb Co | 2.11% | 1.22% |
| Abbott Laboratories | 1.89% | 1.42% |
| Intuitive Surgical Inc | 1.87% | 1.31% |
| Amgen Inc | 1.82% | 1.56% |
| Stryker Corp | 1.78% | 1.21% |
| Elevance Health Inc | 1.53% | 1.02% |
| Danaher Corp | 1.43% | 1.30% |
Source: SEC Form N-PORT
PRHSX top 10
- Eli Lilly & Co — 14.28%
- Johnson & Johnson — 6.63%
- Unitedhealth Group Inc — 5.99%
- Abbvie Inc — 5.10%
- Merck & Co. Inc. — 4.01%
- Gilead Sciences Inc — 2.82%
- Thermo Fisher Scientific Inc — 2.52%
- Vertex Pharmaceuticals Inc — 2.28%
- Bristol-myers Squibb Co — 2.11%
- Abbott Laboratories — 1.89%
RYHIX top 10
- Eli Lilly & Company — 3.63%
- Johnson & Johnson — 2.88%
- Abbvie Inc — 2.52%
- Unitedhealth Group Inc — 2.22%
- Merck & Company Inc — 2.04%
- Thermo Fisher Scientific Inc — 1.61%
- Amgen Inc — 1.56%
- Abbott Laboratories — 1.42%
- Gilead Sciences Inc — 1.39%
- Vertex Pharmaceuticals Inc — 1.34%
FAQ
What is the difference between PRHSX and RYHIX?
Which is cheaper, PRHSX or RYHIX?
Should I own both PRHSX and RYHIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.